HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.

Abstract
The adenosine A2A receptor antagonist, istradefylline improves motor function in patients with advanced Parkinson's disease (PD) optimally treated with a combination of L-DOPA and a dopamine agonist without increasing the risk of troublesome dyskinesia. However, the effects of istradefylline on motor function when administered in combination with low dose of L-DOPA and dopamine agonists as occurs in early PD are unknown. We investigated whether istradefylline enhances the combined anti-parkinsonian effects of a suboptimal dose of L-DOPA and a threshold dose of either the non-ergot dopamine agonist, ropinirole or the ergot dopamine agonist, pergolide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmoset. Threshold doses of ropinirole (0.025-0.075 mg/kg p.o.) and pergolide (0.01 mg/kg p.o.) produced a weak anti-parkinsonian effect. Co-administration of a suboptimal dose of L-DOPA (2.5mg/kg p.o.) with threshold doses of the dopamine agonists enhanced their anti-parkinsonian effect that led to increased 'ON' time without dyskinesia appearing. Administering istradefylline (10mg/kg p.o.) with the threshold doses of dopamine agonists and the suboptimal dose of L-DOPA in a triple combination caused a further enhancement of the anti-parkinsonian response but dyskinesia was still absent. In early PD, dopamine agonists are often used as first-line monotherapy, but efficacy is usually lost within a few years, at which time L-DOPA is added but with the risk of dyskinesia appearance. These results show that istradefylline is effective in improving motor function in combination with low dose dopaminergic drug treatment without provoking dyskinesia.
AuthorsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 766 Pg. 25-30 (Nov 05 2015) ISSN: 1879-0712 [Electronic] Netherlands
PMID26415982 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Elsevier B.V. All rights reserved.
Chemical References
  • Adenosine A2 Receptor Antagonists
  • Antiparkinson Agents
  • Dopamine Agonists
  • Indoles
  • Purines
  • ropinirole
  • Pergolide
  • istradefylline
  • Levodopa
Topics
  • Adenosine A2 Receptor Antagonists (therapeutic use)
  • Animals
  • Antiparkinson Agents (therapeutic use)
  • Behavior, Animal (drug effects)
  • Callithrix
  • Dopamine Agonists (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Indoles (therapeutic use)
  • Levodopa (therapeutic use)
  • MPTP Poisoning (chemically induced, drug therapy)
  • Male
  • Motor Activity (drug effects)
  • Pergolide (therapeutic use)
  • Purines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: